
10/04/2024
None! The FDA approved 503a & b compound pharmacies that have ovaries, will continue to supply their current patients, but will pause accepting new patients until the shortage resolution has been deemed false…which we all know it is and a mafia move by Eli Lilly.
Read this carefully - they included loopholes: https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize)
This ONLY (and I’m convinced temporarily) affects Tirzepatide, not any other GLP1.
Even through the worst of shortages and supply chain issues (which the FDA mentions here), Eli Lilly has been pressuring the FDA to declare the shortage over.
If you ask why, follow the $$$ (who is making it and who is losing it).
Do not panic. They are counting on our fear. I have ovaries, so I don’t scare easily especially when it involves the health of my patient.